Focus: Novartis investors turn spotlight on M&A after trial setbacks

Novartis faces increased investor scrutiny of its M&A strategy after setbacks involving acquired drugs pressured its shares and raised concerns over the durability of its pipeline. The developments create a negative overhang for the company’s dealmaking credibility and medium-term growth outlook.